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Summary.-The effects of cis-dichlorodiammine platinum II (DDP) on the intestinal
mucosa and the kidney were studied after single and multiple treatments with inter-
vals of7-45 days. After a single treatment, thejejunal epithelium underwent a trans-
ient interruption of cell proliferation followed by a hyperplastic recovery and return
to control proliferative rate on Day 7. Subsequent treatments led to suboptimal re-
covery for all treatment intervals. In contrast, DDP induced a 6-fold increase in
[3H]dT incorporation in the kidney by Day 7 which remained high until Day 21, and
returned to near-control values by Day 45. After a single DDP treatment, the "re-
covery potential" of kidneys, measured by the proliferative response to folic-acid
stress, demonstrated suboptimal proliferative reserve compartments for up to 45
days. The distinction between acute and delayed sensitivity to subsequent drug
treatment was more apparent in the DDP-treated kidney than in the intestinal
epithelium.
CIS-DICHLORODIAMMINE PLATINUA II
(DDP) has been reported to be effective
against a number of tumours in animals
(Welsch, 1971; Douple et al., 1977;
Presnov et al., 1978) and in man (Higby
et al., 1974; Wallace & Higby, 1974;
Yagoda et al., 1978).
The most serious toxic side-effects
result from damage to the renal tubules
(the dose-limiting tissue in man), the
gastrointestinal epithelium and the mar-
row (Taylor et al., 1976; Gonzales-Vitale
et al., 1977; Presnov et al., 1978; Lehane
et al., 1979).
The use of chemotherapeutic agents
such as DDP in regimens designed (1) to
recruit additional non-proliferating neo-
plastic cells into the cell cycle, (2) to
modify the cycling characteristics (e.g.
synchronize), or (3) to enhance tumour
cytotoxicity by multiple treatments may
also produce unforeseen damage to the
dose-limiting organs and cells of rapidly
proliferating normal tissues. These toxici-
ties usually occur either early after treat-
ment (acute) or are delayed. More recently,
toxicities of a subelinical nature have
been defined (Dentino et al., 1978; Free-
man et al., 1979; Bruno et al., 1980) which
are very often manifestations of transient
or long-lasting reduction in proliferative
reserves of the normal cell-renewal sys-
tems.
In the present studies we have investi-
gated the proliferative reserve of both the
gastrointestinal and renal-tuble epithelium
after single and sequential treatments with
DDP.
MATERIALS AND METHODS
Animal treatment
Male BDF1 mice (Jax) used throughout
these studies w- ere housed, 5 mice/cage, in
animal quarters -with a 12 h photoperiod.
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Mice were fed standard mouse chow (Purina,
Evanston, Ill.) and water ad libitum. At 7
weeks of age, mice were given their first
i.p. injection of freshly prepared DDP
(8 mg/kg) in 0 9% saline. Subsequently,
specified groups of animals were treated with
a second 8 mg/kg dose of DDP at either 7,
14, 21 or 45 days after the initial treatment.
DDP (NSC 119875-I) was supplied by Dr
H. B. Wood, Drug Synthesis and Chemistry
Branch, DCT, National Cancer Institute.
Measurement of proliferative activity in in-
testinal and renal tissues
Each animal was injected i.p. with 25 ,tCi
of 3H-methyl-thymidine ([3H]dT sp. act.
2 Ci/mmol, Schwarz/Mann, Orangeburg,
N.Y.). Thirty minutes later, the mice were
killed and 4 cm segments of jejunum and
both kidneys were removed. Immediately
after excision, tissue were placed in iced
saline. The tissues were cleaned, the jejunum
slit to remove luminal contents, rinsed in
saline, blotted to remove adherent moisture
and weighed. The left kidney was fixed in
buffered formalin, embedded in paraffin and
4,um sections prepared for autoradiography
(ARG) using Kodak NTB-2 emulsion. The
slides were exposed at 4°C for 21 days and
developed with Kodak D-19. The ARGs were
stained through the emulsion with haema-
toxylinand counterstained withacidifiedeosin
and coverslipped. For microscopic analysis, a
cell was considered labelled if it contained
5 or more grains per nucleus. Labelling indices
(LI) were determined by counting at least
3000-5000 cells in the renal cortex. The
labelled fraction was expressed as a percent-
age. The mean grain count of labelled cells
was >25 grains per cell. Glomerular, medul-
lary and interstitial cells were not counted.
The local background for the ARGs was
2-3 grains per cell.
The right kidney and the jejunal segment
were fixed in 3: 1 absolute alcohol:acetic
acid for 24 h, which removes unincorporated
label (Burholt et al, 1977). The tissues were
then solubilized in Soluene (New England
Nuclear, Boston, MA) and the radioactivity
counted in a liquid-scintillation spectrometer
with internal quench correction and absolute
activity analyser. The results for the intestine
were expressed on a tissue-weight basis
(d/min/mg wet wt) while the results for the
kidney were expressed on an organ basis
(d/min/kidney).
Measurement ofproliferative reserve in treated
renal tissue
The proliferative reserve of the renal
tubule epithelium as a function of time after
DDP treatment was assessed by evaluating
[3H]dT uptake after folic acid (FA)-induced
acute nephrotoxic tubular necrosis. FA was
administered i.p. in0.9% NaClasa suspension
(100 mg/kg). This dose was previously found
to be non-lethal for this strain and age of
mouse.
At either 7, 14, 21, or 45 days after DDP
treatment, the mice were weighed and
individually dosed with 100 mg/kg FA.
At intervals of 24 h the mice were injected
with 25 ,uCi of [3H]dT and killed 30 min
later. As described above, the right kidney
was assessed for [3H]dT incorporation and
the left kidney prepared for ARG.
Calculation of proliferative reserve deficit in
treated intestinal and renal tissues
Assuming that all cells that take up [3H]dT
are proliferating the d/min/mg tissue and
d/min/kidney time-course curves are pro-
portional to the total cell production follow-
ing treatment.
Intestine-Intestinal-response deficit (IRD)
was estimated by the integrated cell produc-
tion (area under curve; AUC) after the
second treatment as a percentage of AUC
after a single treatment.
IRD= I-(AUC for multiple treatmentA
L \ AUC for single treatment!
x 100%]
Kidney.-Therenal -response deficit (RRD)
was estimated by the integrated cell produc-
tion after 100 mg/kg FA given at various
times after DDP treatment as a percentage
of that after 100 mg/kg FA in untreated
kidneys. The ratios for cell production
measured by both ct/min/kidney and LI
were compared.
RRD= I - AUC for multipletreatments
L a ~AUC for single treatment)
x 100%
RESULTS
Single treatment with 8 mg/kg DDP
After a single injection of DDP, trans-
ient interruption in jejunal proliferation
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FIG. 1. Effect of a single dose ofDDP (8 mg/kg) on the proliferative activity of the intestine and
kidney in BDF1 mice. Each point represents mean ( + s.e.) of the data from 5 animals.
was noted up to 36 h with subsequent
compensatory hyperplasia between 48
and 144 h (Fig. 1). Cell production then
returned to control levels (7 days) and
remained so throughout the next 38 days
of observation.
Unlike the intestine, the kidney, nor-
mally associated with low rates of cell
production, was not immediately affected
by a single injection of DDP. Within
48 h of treatment, however [3H]dT incor-
poration into the kidney gradually in-
creased, reaching a maximum (740% of
untreated control) on Day 7 (Fig. 1).
Proliferation gradually returned to nearly
control levels by Day 45 (145% ofcontrol).
Sequential treatment with 8 my/kg DDP
After the initial DDP treatment, a
second dose of 8 mg/kg DDP was given
to animals on Days 7, 14, 21 or 45. In-
testinal proliferation at the time of the
second treatment had returned to control
levels. Recovery after the second DDP
treatment was subnormal at all intervals
up to 45 days (Fig. 2). Proliferative peaks
after the second treatment occurred earlier
(72 h) and were lower. Cell production
over the 120 h period after treatment on
Days 0+ 7 and Days 0+ 45 was about
65% of that after a single treatment,
whilst for Days 0+14 and Days 0+21,
cell production was 80% of groups receiv-
ing a single treatment (Table I).
Unlike the intestine, the proliferative
activity in the kidney at the time of the
second treatment was higher than control,
untreated levels (Fig. 3). A second treat-
ment on Day 7, when the kidney is at
its proliferative maximum, produced a
60% reduction in [3H]dT uptake by 24 h.
During the next 96 h, [3H]dT incorpora-
tion remained depressed, and in a subse-
quent experiment, treatment on DaysDDP-INDUCED PROLIFERATIVE DEFECTS
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FiG. 2.-The effect of the interval between
treatments during sequential DDP treat-
ment (8 mg/kg/dose) on the proliferative
activity of the intestinal epithelium. Zero
time for each curve is the time of the last
DDP treatment. Each point represents the
mean ( ± s.e.) for 5 animals.
TABLE L.-Response of the intestinal
epithelium to multiple treatments with
DDP
2nd Treatment*
(days)
0 (control) §
+7
+14
+21
+45
Integrated cell
production
d/min/mgt
(%) IRD$
100
67
82
82
69
0
33
18
18
31
* 8 mg/kg DDP.
t Area under the [3H]dT d/min/mg wet wt
curve.
: Response deficit calculated from the
intestinal d/min/mg curve.
§ All animals received 8 mg/kg DDP at
Day 0.
0 + 7 produced a 40% mortality ofanimals
by Day 10 after treatment. A second treat-
ment on Days 14 or 21 also depressed
proliferation (by
- 40%) but, unlike the
0+7 group, recovery and compensatory
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FiG. 3.-The effect of the interval between
treatments during sequential DDP treat-
ment on the [3H]dT uptake in the kidney.
Each point represents the percentage ofthe
[3H]dT incorporation value at the time of
the final treatment (to). The absolute to
values (d/min/kidney ± s.e.) for each curve
are given on the right of the figure and
demonstrate the changing proliferative
activity with time from a single DDP in-
jection. Each point represents the data for
5 animals.
hyperproliferation were seen between 96
and 120 h. A second treatment on Day
45 did not substantially reduce [3H]dT
incorporation. On the contrary there was
a gradual increase in proliferative activity
through 96 h, thereafter falling rapidly
to [3H]dT incorporation rates of 45%
of the initial level by 120 h.
Proliferative reserve in renal tissue during
sequential treatment
To measure the proliferative recovery
potential in renal tissues after a single
treatment with DDP, FA-induced tubular
necrosis was used as an acute proliferative
stimulus. After FA (100 mg/kg) treat-
ments, the kidneys were yellow in colour
with areas of focal haemorrhage. Histo-
logically, the tubular epithelium was
dilated and contained casts (areas not
staining with H. & E.). Occasional necrotic
and degenerative changes were seen in the
tubular epithelial cells within 24 h of FA
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Fia. 4. [3H]dT uptake in the kidney after 100 mg/kg FA as a function of time after DDP treatment.
(e), untreated animals; (0), animals treated with 8 mg/kg DDP on Day 0. Each point represents the
mean + s.e. for 5 animals.
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FIG. 5. Renal tubular epithelial cell proliferation (LI) following 100 mg/kg FA as a function of time
after DDP treatment. (0), untreated animals; (0), animals treated with 8 mg/kg DDP on Day 0.
Each point represents the mean + s.e. for 5 animals.
treatment. The [3H]dT uptake in control
kidneys was increased by 24 h after FA
stress, with maximal incorporation at
72 h (Fig. 4). For all intervals, the pro-
liferative renal response to FA stress was
subnormal. The data suggested a recovery
of the proliferative reserve between 7
and 14 days. However, a progressive
decrease in compensatory proliferative
response to FA was seen between 14
and 45 days.
Fig. 5 demonstrates the changes in the
[3H]dT labelling index (LI) for tubular
epithelium in the renal cortex after FA
stress (100 mg/kg). In the control animals,
LI was significantly increased by 24 h,
reaching a maximunm (increased 120-fold)
at 72 h and falling rapidly at 96 h. InDDP-INDUCED PROLIFERATIVE DEFECTS
TABLE II.-Response of the renal tubular
epithelium to multiple treatments with
DDP
(Effect of FA proliferative stimulus after initial
Treatment*
(days)
0 (control)
+7
+14
+21
+ 45
DDP treatment)
Integrated cell production (%)
LIt
100
59
87
59
29
d/min/kidneyt RRD§
100 0
48 46
87 13
34 53
24 74
* Time of FA stress following DDP treatment.
t Area under the [3H[dT LI curve.
: Area under the [3H]dT d/min/kidney curve.
§ Combined response deficit of LI and d/min/
kidney response
pretreated mice, LIs before FA stress were
significantly higher than control. On Days
7 and 14 after DDP, the LI was 20 and
10 times the control, respectively. Not
unlike the [3H]dT uptake data (Fig. 4),
the renal response to FA stress demon-
strated a subnormal proliferative reserve
for all intervals studied up to day 45
after DDP treatment.
If all tubular cells that took up [3H]dT
were subsequently to divide, the area
under the d/min/kidney and LI time-
course curves would be proportional to the
total cell production during the experi-
ments. Table II illustrates the changes
in net cell production induced by FA as
a function of the time after an initial
DDP treatment. In general, the magnitude
of cell production estimated from the LI
curve was greater than that estimated by
d/min/kidney. However, the relative de-
ficits in integrated cell production calcu-
lated from these two indices were similar.
The response deficits on Days 7 and 21
were similar. However, on Day 14 the
response deficit was at a minimum,
separating acute DDP renal effects from
a significant and progressively increasing
long-term reduction in renal proliferative
reserve.
DISCUSSION
The results from these studies demon-
strate the response of two different normal
tissues to cis-platinum II. In the rapidly
proliferating intestinal epithelium, DDP
produces a transient inhibition of cell
production, followed by a compensatory
recovery and a return to steady-state con-
trol levels 7 days after treatment (Fig.
1). The time course and magnitude of
this response have been found to be dose-
dependent (Phillips & Fu, 1976; Burholt
et a., 1979; Luk et al., 1979), suggesting
that the drug alone is cytotoxic to the
intestinal crypt cells. In addition, DDP
has been found to enhance the gastro-
intestinal radiosensitivity in combined
radiation+drug studies (Luk et al., 1979;
Schenken et al., 1979a).
By comparison, renal-tubule cell pro-
liferation is not markedly affected by
DDP treatment (Fig. 1). Incorporation
of [3H]dT is only slightly depressed during
the first 24 h after treatment, increasing
after 3 days and reaching a 6-fold increase
on Day 7. Taylor et al. (1976) have re-
ported similar observations in rats treated
with 4 0 mg/kg DDP. However, they
observed an initial marked inhibition of
DNA synthesis before a 16-fold increase
by Day 7. Cell proliferation in the kidney
under non-stress conditions as monitored
by d/min/kidney reflects proliferation of
transitional and squamous epithelium
rather than tubular epithelium, which is
extremely low. This may explain the dis-
crepancy between the initial renal re-
sponse to DDP reported here and that
observed by Taylor et al. (1976). In addi-
tion, there may be interspecific differences
in drug dose as suggested by Litterst
et al. (1979).
Treatments after the first dose of DDP
led to suboptimal recovery of the jejunal
epithelium for intertreatment times up to
45 days (Fig. 2). Both the magnitude and
time of compensatory proliferative peaks
were reduced. While steady-state prolifera-
tive conditions were restored by Day 7,
the response deficits calculated for subse-
quest treatments up to 45 days (Table I)
suggested that DDP in sequential proto-
cols would enhance the intestinal drug
sensitivity. Second treatments on Days
7 or 45 were less well tolerated than those
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on Days 14 or 21. Similar enhanced drug
sensitivity was found in the kidney after
an initial treatment with DDP (Figs
4 & 5; Table II). Again a subsequent
treatment on Day 14 appeared more toler-
able than after the other treatment inter-
vals. In the kidney, the distinction be-
tween early (acute) and delayed enhance-
ment of sensitivity was more apparent.
Delayed complications after both drug
and radiation therapy have been recog-
nized in a number of normal tissues
(Phillips & Fu, 1976; Nygaard et al.,
1976). Schenken et al. (1979b), have re-
cently demonstrated enhanced gastro-
intestinal radiosensitivity by Adr, where
the drug and radiation treatments were
separated by 14-49 days. Similarly to our
observations for sequential drug treat-
ment, they observed that radiosensitivity
diminished from the time of drug treat-
ment until 14 days, and then progressively
increased in severi-ty for up to 49 days.
Enhanced tissue sensitivity, when inter-
treatment times are short is probably a
direct result ofthe interaction ofthe treat-
ment modalities on the cell-proliferation
kinetics ofthe tissue. Enhanced sensitivity
arising from longer treatment intervals,
however, is most probably a manifestation
of reduced proliferative reserves in the
normal cell-renewal systems (Schenken
et al., 1979b; Braunschweiger et al.,
1980; Morley, 1980).
Dentino et al. (1978) have reported
permanent, nonspecific functional renal
injury in patients treated with DDP.
They suggested that ". . . while renal
injury remained subclinical, future courses
of DDP could lead to clinically important
renal failure". From the results presented
here, increasing the intertreatment time
from 7 to 14 days appeared to permit
proliferative recovery of the renal tissue
(Fig. 3). None the less, under similar time
considerations, a single dose of 8 mg/kg
DDP produced greater restriction on the
capacity of the proliferative reserve of the
kidney to mount a compensatory response
to FA-induced renal tubular necrosis
(Figs 4 & 5; Table II). Under continued
treatment with DDP, as suggested by
Dentino, subelinical changes in the renal
proliferative reserve could be compounded,
leading to chronic renal failure.
The question remains: "What is the
basis for drug-induced limitation of pro-
liferative reserve in normal tissues?"
Earlier (Schenken et al., 1979b; Kovacs
et al., 1981) it was suggested that the effect
was a manifestation of latent damage to
the stem-cell compartment brought about
by sequestration of sublethal levels of
drug. Alternatively, damage could be
accumulated in a secondary support sys-
tem such as the tissue vasculature. We
have observed that on Day 14 the capacity
of DDP-treated kidneys to mount a com-
pensatory proliferative response to FA
damage is greater than on Days 7, 21 or
45. The half-life of DDP retention in
kidney tissue has been reported as 8-4
days (Taylor et al., 1976) with significant
levels retained tightly bound to tissue
protein and nucleic-acid bases (Taylor
et al., 1973). This could explain the appar-
ent recovery of early damage (Days 0-14)
shown in Fig. 5, where near-normal levels
of cell production (87%; Table II) occur
after FA stress. However, ifdrug retention
alone were responsible for the reductions
in proliferative reserve, and near-normal
responses occurred at Day 14 after drug
treatment, similar or even improved
responses to FA would be expected on
Days 21 and 45. Rather it appears that a
secondary effect, not related to the
immediate drug inhibition ofthe prolifera-
tive reserve, develops at these later times,
and has been found up to 120 days after
the initial treatment (Braunschweiger
et al., 1980, and unpublished).
One could argue that when the kidney
undergoes proliferative recovery, the cell
population of the proliferative reserve is
reduced, thus reducing the overall ability
of the tissue to respond to further prolife-
rative stress. Experimentally inducedrenal
hypertrophy has, however, been exten-
sively studied in both mice and rats
(Baserga et al., 1968; Byrnes etal., 1972a,b)
and these data suggest that the kidney isDDP-INDUCED PROLIFERATIVE DEFECTS 293
capable of responding to a second stress
stimulus (Threlfall et al., 1967). Alter-
natively, long-term exposure to even low
levels of drug could permanently damage
the renal microenvironment, which in
turn could have a net antiproliferative
effect. Dentino et al. (1978) have observed
a regular and persistent decrease in the
glomerular filtration rate of patients after
the second course of DDP; they noted
segmental cellular necrosis in the proximal
and distal tubules at 3-6 weeks after
treatment, and after 5 months focal inter-
stitial fibrosis was evident as well as
tubular atrophy and dilation.
It is as yet unclear whether the under-
lying mechanisms of the long-term toxici-
ties from DDP treatment are similar for
intestinal and renal-tubular epithelium.
However, from a clinical standpoint, the
answer to such a question takes on new
importance, especially for continuing or
recurring therapy. Studies are continuing
to elucidate the nature of, and amelio-
ration of, these potentially harmful effects.
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